Compare Incyte Corporation (INCY) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Waste Management, Inc. — how do they compare? Incyte Corporation trades at $117.61 (market cap $23.11B), while Waste Management, Inc. trades at $234.3 (market cap $96.00B). The key difference: Waste Management, Inc. is far larger — about 4.2× Incyte Corporation's market cap, and Waste Management, Inc. pays a 1.48% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | WM | |
|---|---|---|
Market Cap | $23.11B | $96.00B |
Sector | Health | Industrials |
52-Week High | $118.52 | $246.51 |
52-Week Low | $67.38 | $196.77 |
Enterprise Value | $19.13B | $118.73B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
WM trades at $239.26, showing minimal daily movement with a slight 0.02% decline. The stock maintains a bullish technical outlook with strong moving average signals and trades near its pivot point of $241. Fundamentally, the company demonstrates solid revenue growth from $19.7B in 2022 to $25.2B in 2025, though recent quarters show mixed earnings performance with two misses and one beat against expectations.
WM presents a stable investment case with consistent dividend payments and strong analyst support (57% buy ratings), but faces challenges from elevated debt levels and valuation multiples. The consensus price target of $263.57 suggests 10% upside potential, though investors should monitor execution on earnings guidance and debt management in the coming quarters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
